- Home
- GVH vs IXHL Comparison
GVH vs IXHL Comparison
Compare GVH & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GVH
- IXHL
- Stock Information
- Founded
- GVH 2016
- IXHL 2001
- Country
- GVH Australia
- IXHL Australia
- Employees
- GVH N/A
- IXHL 9
- Industry
- GVH
- IXHL
- Sector
- GVH
- IXHL
- Exchange
- GVH Nasdaq
- IXHL Nasdaq
- Market Cap
- GVH 21.3M
- IXHL 20.5M
- IPO Year
- GVH 2023
- IXHL N/A
- Fundamental
- Price
- GVH $0.18
- IXHL $0.21
- Analyst Decision
- GVH
- IXHL
- Analyst Count
- GVH 0
- IXHL 0
- Target Price
- GVH N/A
- IXHL N/A
- AVG Volume (30 Days)
- GVH 3.2M
- IXHL 38.5M
- Earning Date
- GVH 02-12-2025
- IXHL 05-15-2025
- Dividend Yield
- GVH N/A
- IXHL N/A
- EPS Growth
- GVH 12.04
- IXHL N/A
- EPS
- GVH 0.09
- IXHL N/A
- Revenue
- GVH $16,540,178.00
- IXHL $98,000.00
- Revenue This Year
- GVH N/A
- IXHL $3,817.06
- Revenue Next Year
- GVH N/A
- IXHL $66.67
- P/E Ratio
- GVH $7.56
- IXHL N/A
- Revenue Growth
- GVH N/A
- IXHL N/A
- 52 Week Low
- GVH $0.16
- IXHL $0.08
- 52 Week High
- GVH $1.82
- IXHL $3.37
- Technical
- Relative Strength Index (RSI)
- GVH 22.26
- IXHL 46.27
- Support Level
- GVH $1.33
- IXHL $0.20
- Resistance Level
- GVH $1.54
- IXHL $0.23
- Average True Range (ATR)
- GVH 0.14
- IXHL 0.02
- MACD
- GVH -0.14
- IXHL 0.01
- Stochastic Oscillator
- GVH 0.99
- IXHL 42.50
About GVH Globavend Holdings Limited
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.